Reduced Myocardial Mitochondrial ROS Production in Mechanically Unloaded Hearts

  • Daniel Scheiber
  • Elric Zweck
  • Tomas Jelenik
  • Patrick Horn
  • Sophie Albermann
  • Maryna Masyuk
  • Udo Boeken
  • Diyar Saeed
  • Malte Kelm
  • Michael Roden
  • Julia Szendroedi
  • Ralf Westenfeld
Original Article
First Online:
Received:
Accepted:
  • 33 Downloads

Abstract

Mechanical ventricular unloading in advanced heart failure (HF) has been shown to induce reverse remodeling in myocardial tissues. Little is known about the impact of ventricular unloading on myocardial energy metabolism. We hypothesized that left ventricular unloading reduces myocardial mitochondrial reactive oxygen species (ROS) production and improves mitochondrial coupling efficiency in patients suffering from advanced HF. Left ventricular tissue specimens were harvested from explanted hearts at the time of transplantation. We compared myocardial metabolism in explanted hearts supported with an unloading ventricular assist device prior to transplantation (LVAD-HTX; n = 9) with tissue specimens of unsupported failing hearts (HTX; n = 6). Myocardial mitochondrial ROS production was decreased by 40% in LVAD-HTX compared to HTX patients (1.5 ± 0.3 vs. 0.9 ± 0.1 pmol/(s/mg); p < 0.05). High-resolution respirometry revealed increased mitochondrial coupling efficiency in LVAD-HTX patients (respiratory/control ratio 1.7 ± 0.2 vs. 1.2 ± 0.2; p < 0.05). In conclusion, ventricular unloading is related to decreased mitochondrial ROS production and increased coupling efficiency in myocardium of human failing hearts, suggesting a novel pathomechanism of unloading-associated cardioprotection.

Keywords

Heart failure Left ventricular unloading Left ventricular assist device Heart transplantation Myocardial energy metabolism High-resolution respirometry Mitochondrial respiration Reactive oxygen species 
This is a preview of subscription content, log in to check access

References

  1. 1.
    Dayer, M., & Cowie, M. R. (2004). Heart failure: diagnosis and healthcare burden. Clinical Medicine (London, England), 4(1), 13–18.CrossRefGoogle Scholar
  2. 2.
    Braunwald, E. (2013). Heart failure. JACC Heart Fail, 1(1), 1–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Ponikowski, P., et al. (2016). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 18(8), 891–975.CrossRefPubMedGoogle Scholar
  4. 4.
    Deng, M. C., et al. (2004). Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: second annual report—2004. The Journal of Heart and Lung Transplantation, 23(9), 1027–1034.CrossRefPubMedGoogle Scholar
  5. 5.
    Burkhoff, D., Klotz, S., & Mancini, D. M. (2006). LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery. Journal of Cardiac Failure, 12(3), 227–239.CrossRefPubMedGoogle Scholar
  6. 6.
    Klotz, S., et al. (2004). Left ventricular pressure and volume unloading during pulsatile versus nonpulsatile left ventricular assist device support. The Annals of Thoracic Surgery, 77(1), 143–9; discussion 149-50.CrossRefPubMedGoogle Scholar
  7. 7.
    Ponikowski, P., et al. (2016). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37(27), 2129–2200.CrossRefPubMedGoogle Scholar
  8. 8.
    Levin, H. R., et al. (1995). Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation, 91(11), 2717–2720.CrossRefPubMedGoogle Scholar
  9. 9.
    de Jonge, N., et al. (2002). Left ventricular assist device in end-stage heart failure: persistence of structural myocyte damage after unloading. An immunohistochemical analysis of the contractile myofilaments. Journal of the American College of Cardiology, 39(6), 963–969.CrossRefPubMedGoogle Scholar
  10. 10.
    Vatta, M., et al. (2002). Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet, 359(9310), 936–941.CrossRefPubMedGoogle Scholar
  11. 11.
    Bayeva, M., Gheorghiade, M., & Ardehali, H. (2013). Mitochondria as a therapeutic target in heart failure. Journal of the American College of Cardiology, 61(6), 599–610.CrossRefPubMedGoogle Scholar
  12. 12.
    Lee, S. H., et al. (1998). Improvement of myocardial mitochondrial function after hemodynamic support with left ventricular assist devices in patients with heart failure. The Journal of Thoracic and Cardiovascular Surgery, 116(2), 344–349.CrossRefPubMedGoogle Scholar
  13. 13.
    Nagoshi, T., et al. (2011). Optimization of cardiac metabolism in heart failure. Current Pharmaceutical Design, 17(35), 3846–3853.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Holzem, K. M., et al. (2016). Mitochondrial structure and function are not different between nonfailing donor and end-stage failing human hearts. The FASEB Journal, 30(8), 2698–2707.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stride, N., et al. (2013). Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction. European Journal of Heart Failure, 15(2), 150–157.CrossRefPubMedGoogle Scholar
  16. 16.
    Tsutsui, H., Kinugawa, S., & Matsushima, S. (2011). Oxidative stress and heart failure. American Journal of Physiology. Heart and Circulatory Physiology, 301(6), H2181–H2190.CrossRefPubMedGoogle Scholar
  17. 17.
    Mondal, N. K., et al. (2013). Oxidative stress, DNA damage and repair in heart failure patients after implantation of continuous flow left ventricular assist devices. International Journal of Medical Sciences, 10(7), 883–893.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Templeton, D. L., et al. (2012). Effects of left ventricular assist device (LVAD) placement on myocardial oxidative stress markers. Heart, Lung & Circulation, 21(9), 586–597.CrossRefGoogle Scholar
  19. 19.
    Koliaki, C., et al. (2015). Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metabolism, 21(5), 739–746.CrossRefPubMedGoogle Scholar
  20. 20.
    Szendroedi, J., Phielix, E., & Roden, M. (2011). The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nature Reviews. Endocrinology, 8(2), 92–103.CrossRefPubMedGoogle Scholar
  21. 21.
    Pesta, D., & Gnaiger, E. (2012). High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods in Molecular Biology, 810, 25–58.CrossRefPubMedGoogle Scholar
  22. 22.
    Gnaiger, E. (2008). Polarographic oxygen sensors, the oxygraph, and high-resolution respirometry to assess mitochondrial function. In Drug-induced mitochondrial dysfunction (pp. 325–352).CrossRefGoogle Scholar
  23. 23.
    Gnaiger, E. (2009). Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology. The International Journal of Biochemistry & Cell Biology, 41(10), 1837–1845.CrossRefGoogle Scholar
  24. 24.
    Krumschnabel, G., et al. (2015). Simultaneous high-resolution measurement of mitochondrial respiration and hydrogen peroxide production. Methods in Molecular Biology, 1264, 245–261.CrossRefPubMedGoogle Scholar
  25. 25.
    Makrecka-Kuka, M., Krumschnabel, G., & Gnaiger, E. (2015). High-resolution respirometry for simultaneous measurement of oxygen and hydrogen peroxide fluxes in permeabilized cells, tissue homogenate and isolated mitochondria. Biomolecules, 5(3), 1319–1338.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Fleckenstein-Elsen, M., et al. (2016). Eicosapentaenoic acid and arachidonic acid differentially regulate adipogenesis, acquisition of a brite phenotype and mitochondrial function in primary human adipocytes. Molecular Nutrition & Food Research, 60(9), 2065–2075.CrossRefGoogle Scholar
  27. 27.
    Larsen, S., et al. (2012). Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. The Journal of Physiology, 590(14), 3349–3360.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lemieux, H., et al. (2011). Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart. The International Journal of Biochemistry & Cell Biology, 43(12), 1729–1738.CrossRefGoogle Scholar
  29. 29.
    Dipla, K., et al. (1998). Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation, 97(23), 2316–2322.CrossRefPubMedGoogle Scholar
  30. 30.
    Heerdt, P. M., et al. (2002). Disease-specific remodeling of cardiac mitochondria after a left ventricular assist device. The Annals of Thoracic Surgery, 73(4), 1216–1221.CrossRefPubMedGoogle Scholar
  31. 31.
    Razeghi, P., et al. (2002). Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology, 97(4), 203–209.CrossRefPubMedGoogle Scholar
  32. 32.
    Keith, M., et al. (1998). Increased oxidative stress in patients with congestive heart failure 11This study was supported by a grant jointly sponsored by the Medical Research Council of Canada, Ottawa and Bayer pharmaceuticals, Etobicoke, Ontario, Canada. Journal of the American College of Cardiology, 31(6), 1352–1356.CrossRefPubMedGoogle Scholar
  33. 33.
    Ide, T., et al. (2001). Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circulation Research, 88(5), 529–535.CrossRefPubMedGoogle Scholar
  34. 34.
    Sawyer, D. B., et al. (2002). Role of oxidative stress in myocardial hypertrophy and failure. Journal of Molecular and Cellular Cardiology, 34(4), 379–388.CrossRefPubMedGoogle Scholar
  35. 35.
    Caruso, R., et al. (2012). Severity of oxidative stress and inflammatory activation in end-stage heart failure patients are unaltered after 1 month of left ventricular mechanical assistance. Cytokine, 59(1), 138–144.CrossRefPubMedGoogle Scholar
  36. 36.
    Stanley, B. A., et al. (2011). Thioredoxin reductase-2 is essential for keeping low levels of H(2)O(2) emission from isolated heart mitochondria. The Journal of Biological Chemistry, 286(38), 33669–33677.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Aon, M. A., et al. (2012). Glutathione/thioredoxin systems modulate mitochondrial H2O2 emission: an experimental-computational study. The Journal of General Physiology, 139(6), 479–491.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Molina, A. J., et al. (2016). Skeletal muscle mitochondrial content, oxidative capacity, and Mfn2 expression are reduced in older patients with heart failure and preserved ejection fraction and are related to exercise intolerance. JACC Heart Fail, 4(8), 636–645.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Melenovsky, V., et al. (2017). Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. European Journal of Heart Failure, 19(4), 522–530.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Daniel Scheiber
    • 1
    • 2
    • 3
  • Elric Zweck
    • 1
    • 2
    • 3
  • Tomas Jelenik
    • 2
    • 3
  • Patrick Horn
    • 1
  • Sophie Albermann
    • 1
    • 2
    • 3
  • Maryna Masyuk
    • 1
  • Udo Boeken
    • 4
  • Diyar Saeed
    • 4
  • Malte Kelm
    • 1
    • 5
  • Michael Roden
    • 2
    • 3
    • 6
  • Julia Szendroedi
    • 2
    • 3
    • 6
  • Ralf Westenfeld
    • 1
  1. 1.Division of Cardiology, Pulmonology and Vascular Medicine, Medical FacultyHeinrich Heine UniversityDüsseldorfGermany
  2. 2.Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes ResearchHeinrich Heine UniversityDüsseldorfGermany
  3. 3.German Center for Diabetes Research (DZD e.V.)DüsseldorfGermany
  4. 4.Clinic for Cardiovascular Surgery, Medical FacultyHeinrich Heine UniversityDüsseldorfGermany
  5. 5.Cardiovascular Research Institute Duesseldorf, Medical FacultyHeinrich Heine UniversityDüsseldorfGermany
  6. 6.Department of Endocrinology and Diabetology, Medical FacultyHeinrich Heine UniversityDüsseldorfGermany

Personalised recommendations